# TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

> **NCT01851369** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 93 (actual)

## Conditions studied

- Lymphomas
- Solid Tumors
- NSCLC
- Metastatic Colon Carcinoma
- Granulosa Cell Ovarian Cancer

## Interventions

- **DRUG:** TRC102
- **DIAGNOSTIC_TEST:** CT scan
- **OTHER:** Lomotil
- **OTHER:** Prochlorperazine
- **OTHER:** Metoclopramide
- **OTHER:** 5-HT3 antagonist
- **OTHER:** Aprepitant
- **PROCEDURE:** Biopsy

## Key facts

- **NCT ID:** NCT01851369
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-12
- **Primary completion:** 2023-08-01
- **Final completion:** 2023-08-01
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2024-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01851369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01851369, "TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01851369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*